Quartz·1 min read·easy
Eli Lilly is buying a psychedelic drugmaker in a $2.8 billion deal
✦AI Summary
Eli Lilly has announced a $2.8 billion acquisition of a psychedelic drugmaker. The deal grants the pharmaceutical giant access to a DMT-based nasal spray currently designated as a breakthrough therapy for treatment-resistant depression.
The deal gives Lilly access to a DMT-based nasal spray for treatment-resistant depression that has received FDA Breakthrough Therapy Designation
businesshealth
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in